Navigation Links
Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
Date:4/14/2009

COSTA MESA, Calif., April 14 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced it has reached a development and commercial supply agreement with Hospira Inc.'s One 2 One(R) Global Pharmaceutical Services business unit to manufacture clinical-grade Oxycyte(R). Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier. Oxycyte will be manufactured at Hospira's Clayton, North Carolina, facility which specializes in emulsion technology.

Hospira will formulate, fill, finish and label Oxycyte to meet clinical good manufacturing practice (GMP) standards required for use of drugs in human patients. The amount of Oxycyte supplied by Hospira will be sufficient to meet any expected demand for the foreseeable future.

"This agreement connects us to a first-tier contract manufacturer and superbly reliable supplier who will provide us with all the Oxycyte we need to grow the company. As I've previously stated, our strategy is to license marketing rights for individual indications, yet always control the supply of our compound and be able to profit from sales of Oxycyte to licensees," said Chris J. Stern, company chairman and CEO.

The companies are not disclosing the financial terms of the supply agreement.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to licensing and partnering of Oxycyte indications and plans to profit from the sale of Oxycyte to such licensees and partners. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that the company will be able to license or partner Oxycyte for any indications or that sale of Oxycyte to licensees and partners will generate profits for the company. Nor can there be any assurance that any Oxycyte-based products will reach the market. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
2. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
3. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
4. Oxygen Biotherapeutics, Inc. Expands Board of Directors
5. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
6. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
7. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
8. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
9. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
10. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
11. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... for the Semiconductor, MEMS, and Microfluidics Industries, announces the new Model 800E front ... more often in automated production mask aligners. OAI has already received and ...
(Date:8/16/2017)... ... August 16, 2017 , ... Tunnell Consulting announced today that ... ISPE Annual Meeting and Expo , to be held October 29 through November ... is “Driving innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo ...
(Date:8/16/2017)... Philadelphia, PA (PRWEB) , ... August 16, 2017 , ... ... thought, they are much more closely connected than one might think. A Mesh ... Grizzly, will open at the University City Science Center’s Esther Klein Gallery (EKG) on ...
(Date:8/16/2017)... Mass. , Aug. 16, 2017  This year,s edition of the ... leader in life sciences workforce solutions, has made the list for the ... 5000 recognizes the nation,s fastest-growing private companies based on a set of ... 50, which includes the fastest-growing companies in the Bay State ... Inc. 5000 ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):